...
首页> 外文期刊>Medicine. >Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery
【24h】

Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery

机译:在接受疗法手术的IIIA-N2非小细胞肺癌患者中诱导化疗后正电子发射断层扫描 - 计算断层扫描的解释和预测值

获取原文

摘要

We evaluate the correlation of clinical staging on positron emission tomography-computed tomography (PET-CT) and pathologic staging and the prognostic value of PET-CT after induction chemotherapy in patients with locally advanced nonsmall cell lung cancer (NSCLC). We analyzed 42 cases of clinical stage IIIA-N2 NSCLC who receive 2 to 4 cycles of preoperative chemotherapy with or without radiation followed by curative resection. The maximum standard uptake value (SUVmax) of the suspected lesion on PET-CT was recorded. PET-CT findings after induction chemotherapy were compared with those of initial PET-CT and pathology after surgery. The accuracy of PET-CT in restaging of the primary tumor after induction chemotherapy was 50.0%. Eighteen (42.8%) of 42 patients were underestimated ycT stage, and 3 (7.1%) of 42 patients was overestimated ycT stage by PET-CT scan. The accuracy of PET-CT in restaging of the nodal disease was 71.4%. Six (14.3%) of 42 patients were underestimated ycN stage, and 6 (14.3%) of 42 patients were overestimated ycN stage as compared with pathologic staging. The 2-year overall survival (OS) and relapse-free survival (RFS) rate were 68.5% and 40.9%, respectively. Complete responders (ycT0N0M0) on PET-CT after induction chemotherapy had a significantly longer RFS time than did incomplete responders (28.3 vs 9.1 months, P = 0.021). Complete response on PET-CT after induction chemotherapy with or without radiation was a good prognosticator for RFS in stage IIIA-N2 NSCLC patients who received surgery. However, response evaluation on PET-CT after induction chemotherapy should be interpreted with caution due to its unacceptable accuracy.
机译:我们评估临床分期对正电子发射断层摄影层析成像(PET-CT)和病理分期和病理分期的相关性,并且PET-CT在局部先进的NONSMALL细胞肺癌(NSCLC)患者中的诱导化疗后PET-CT的预后价值。我们分析了42例临床阶段IIIA-N2 NSCLC,他们接受2至4个术前化疗的术前化学疗法,然后疗法分析。记录了PET-CT上可疑病变的最大标准摄取值(SUVMAX)。将诱导化疗后的PET-CT结果与初始PET-CT和手术后病理相提并论。诱导化疗后重新肿瘤重新肿瘤重新肿瘤的精度为50.0%。通过PET-CT扫描,18例(42.8%)42名患者的42例患者被低估了YCT阶段,32例患者均多过多为YCT阶段。 PET-CT在重新衰竭节点疾病中的准确性为71.4%。与病理分期相比,六(14.3%)的42例患者均低估了YCN阶段,62例患者的42例患者均多升高了YCN阶段。 2年的总体存活(OS)和无复发存活(RFS)率分别为68.5%和40.9%。在感应化疗后,PET-CT上的完整响应者(YCT0N0M0)比不完全的响应者有明显更长的RFS时间(28.3 Vs 9.1个月,P = 0.021)。在具有或不带辐射的感应化疗后对PET-CT的完全反应是IIIA-N2 NSCLC患者的RFS的良好预测器,接受手术。然而,由于其不可接受的准确性,应谨慎地解释对感应化疗后PET-CT的响应评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号